PARIS (Reuters) - Private equity group PAI Partners expects to receive bids for its French lab testing chain Cerba on Dec. 8 in a deal that could be worth as much as 1.8 billion euros ($1.92 billion), two sources close to the matter said on Friday.
PAI Partners bought Cerba in 2010 for 551 million euros and hired JP Morgan (JPM.N) and Natixis earlier this year for a sale process.
Cerba operates clinical pathology laboratories in Europe with a number one position in France and strong market positions in Belgium, Luxembourg and Africa, according to PAI’s website.
PAI Partners could not immediately be reached for comment.
Reporting by Matthieu Protard. Editing by Jane Merriman